How do you pay?

How to pay the least

Ask for the cash price

Jaypirca

We didn’t find one.

  1. Ask your pharmacy for Jaypirca’s cash price, and one or two other pharmacies too.
  2. Jaypirca’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Lilly Cares Foundation Patient Assistance Program. Note: These income limits are 300% (Group 1 Medications), 400% (Group 2 Medications), and 500% (Group 3 & 4 Medications) of 2026 Federal Poverty Guidelines. Or call 1-800-545-6962.

See if you qualify 

Compare every option

Question
Brand nameJaypirca
Authorized genericpirtobrutinib
Regular genericpirtobrutinib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Jaypirca?
The original
–
–

Brand nameThe maker’s card

Jaypirca Savings Card

Savings card from Eli Lilly

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

The card takes up to $10,600 a year off your co-pay.

Sign up on jaypirca.lilly.com 

Or call 1-833-727-4589.

In the maker’s words

“Pay as little as $0 a month with the Jaypirca Savings Card, if eligible and commercially insured with coverage for Jaypirca…”

From the maker’s offer on jaypirca.lilly.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Jaypirca itself, from the same company, sold without the brand name, and usually for less. For now Jaypirca is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

JAYPIRCA® is a kinase inhibitor indicated for the treatment of:

  • Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor..

Source: the FDA label for Jaypirca (Eli Lilly and Company), March 6, 2026. Full label on DailyMed 

Good to know